X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RBN-3143, a first-in-class, oral small molecule inhibitor of PARP14 which leads to a decrease in alarmins and dampening of the IL-17 and IL-4/13 signaling pathways. It is being developed for moderate-to-severe atopic dermatitis.
Lead Product(s): RBN-3143
Therapeutic Area: Dermatology Product Name: RBN-3143
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
Details:
Ribon plans to use the proceeds to support clinical development of its potentially first-in-class oral small molecule programs in oncology (RBN-2397, a PARP7 inhibitor) and immunology (RBN-3143, a PARP14 inhibitor).
Lead Product(s): RBN-2397,Pembrolizumab
Therapeutic Area: Oncology Product Name: RBN-2397
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 30, 2023
Details:
Boehringer Ingelheim aims to develop novel therapies based on Ribon’s CD38 program to transform the lives of patients with immunological and fibrotic diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 29, 2022
Details:
RBN-3143, a first-in-class, orally administered, small molecule inhibitor of PARP14, has the potential to be a differentiated therapy for the treatment of numerous inflammatory diseases.
Lead Product(s): RBN-3143
Therapeutic Area: Dermatology Product Name: RBN-3143
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
RBN-2397 is an orally available small molecule inhibitor of PARP7 being developed for the treatment cancer. RBN-2397 has been shown to directly inhibit cellular proliferation and restore interferon signaling to stimulate an innate and adaptive antitumor immune response.
Lead Product(s): RBN-2397,Pembrolizumab
Therapeutic Area: Oncology Product Name: RBN-2397
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2022
Details:
Ono will have the exclusive rights to develop and commercialize RBN-2397 in the Ono Territory. Additionally, Ono will have the right to participate in global clinical studies of RBN-2397 by bearing the costs of such studies in the Ono Territory.
Lead Product(s): RBN-2397
Therapeutic Area: Oncology Product Name: RBN-2397
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: $148.3 million Upfront Cash: $16.3 million
Deal Type: Collaboration February 02, 2021
Details:
RBN-2397 restores type I IFN signaling in the tumor, causes complete tumor regressions and adaptive immunity in preclinical models.
Lead Product(s): RBN-2397
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
This presentation will highlight 3 ongoing clinical activities of the company which includes data on a selective PARP14 Inhibitor and RBN-2397 in Treatment of cancer.
Lead Product(s): RBN-2397
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
